Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationale

por Kern, Johannes S., Schwieger-Briel, Agnes, Löwe, Sandra, Sumeray, Mark, Davis, Charles, Martinez, Anna E.
Publicado 2019

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine

por Leroux-Roels, Isabel, Bruhwyler, Jacques, Stergiou, Lilli, Sumeray, Mark, Joye, Jasper, Maes, Cathy, Lambert, Paul-Henri, Leroux-Roels, Geert
Publicado 2023

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension

por Smith, William B., Marbury, Thomas C., Komjathy, Steven F., Sumeray, Mark S., Williams, Gregory C., Hu, Ming-yi, Mould, Diane R.
Publicado 2012

OR23-04 Treatment Of Chronic Hypoparathyroidism With Eneboparatide (AZP-3601), A Novel PTH 1 Receptor Agonist: Results From A Phase 2 Trial

por Kamenicky, Peter, Takacs, Istvan, Mezosi, Emese, Soto, Alfonso, Figueres, Lucile, Lemoine, Sandrine, Borson-Chazot, Francoise, Capel, Ismael, Angeles Artazcoz Galvez Moreno, Maria Angeles, Ovize, Michel, OuldRouis, Taha, Allas, Soraya, Sumeray, Mark, Mannstadt, Michael
Publicado 2023

SAT237 AZP-3601, A Novel PTH 1 Receptor Agonist, Induces Rapid Reduction And Normalization Of Urinary Calcium In Chronic Hypoparathyroid Patients

por Figueres, Lucile, Takacs, Istvan, Mezosi, Emese, Soto, Alfonso, Kamenicky, Peter, Lemoine, Sandrine, Borson-Chazot, Francoise, Capel, Ismael, Angeles Artazcoz Galvez Moreno, Maria Angeles, Ovize, Michel, OuldRouis, Taha, Allas, Soraya, Sumeray, Mark, Mannstadt, Michael
Publicado 2023